Compare GSK plc (GSK) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs TORM plc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while TORM plc trades at $39.94 (market cap $4.12B). The key difference: GSK plc is far larger — about 22.3× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and TORM plc for 23 Days on average.
| GSK | TRMD | |
|---|---|---|
Market Cap | $91.88B | $4.12B |
Volume | 7,730,529 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $61.18 | $41.05 |
52-Week Low | $43.24 | $19.39 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $111.88B | $4.83B |
Dividend Yield | 3.9% | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
TRMD trades at $40.06, up 2.93% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 35.52% net income margin and attractive valuation ratios, including a P/E of 6.59. Recent earnings saw a beat in Q4 2025 but misses in Q1 and Q2 2026, while Q3 2026 results are pending. A $2.40 dividend is scheduled for September 2026, and cash flow trends improved to a net positive in 2026. Analyst consensus is unanimously bullish with 100% buy ratings.
The outlook for TRMD is positive due to robust fundamentals and strong analyst support, but near-term risks include volatile spot rates impacting revenue and insider selling. The stock's valuation remains compelling, though dependence on freight rate sustainability poses a headwind. Investors should weigh the high dividend yield against cyclical industry exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
